Syensqo and Allozymes, a Singaporean enzyme engineering start-up, announced the signing of a Memorandum of Understanding (MOU) to leverage both companies strengths in biotechnology towards the development of advanced biosolutions for Home and Personal Care, in particular for the skin care market.
Allozymes stands out in the bio-engineering sector with its unique ultra-high throughput microfluidics platform for the engineering of enzymes and microbes. The platform enables the rapid and cost-effective development of biomanufactured ingredients and bioprocesses, setting a new standard for innovation and sustainability in the industry.
“By combining Allozymes technological capabilities with Syensqo’s application and market access expertise, we are poised to create ground-breaking solutions that will not only benefit the home and personal care market, but also contribute to a more sustainable future,” said Thomas Canova, head of renewable materials and biotechnology growth platform at Syensqo.
As per the press release, the MOU marks an important milestone in Syensqo’s strategic agenda of rapidly expanding its beauty specialty ingredients portfolio based on biotechnology. It complements the company’s recent acquisition of South Korean ceramides specialist JinYoung Bio, further solidifying its commitment to enabling sustainable and innovative care solutions.
“Our partnership with Syensqo embodies our mutual commitment to a sustainable future, leveraging biotechnology to enable cleaner, greener processes, ensuring our actions today contribute to a healthier planet for future generations. Together, we’re setting a new standard for environmental stewardship,” added Peyman Salehian, PhD, CEO and cofounder at Allozymes.
